At Mikrobiomik, we are moving towards a new milestone in microbiome-based medicine.
Bilbao, Spain — At Mikrobiomik, we are moving towards a new milestone in microbiome-based medicine. As reported by El Economista in a recent interview with our executive director, Patricia del Río, the company plans to launch the first authorised human microbiome therapy in Spain in 2026, aimed at treating recurrent Clostridioides difficile infection.
Our therapy, EUTEGRA (MBK-01), is an encapsulated and standardised fecal microbiota treatment, developed under strict pharmaceutical quality standards (GMP). It is in an advanced stage of clinical development and responds to an unmet medical need, particularly relevant in a context marked by repeated antibiotic use and increasing antimicrobial resistance.
‘Our goal is to transform the therapeutic potential of the microbiome into safe, effective and accessible medicines that are fully integrated into the healthcare system,’ says Patricia del Río, CEO of Mikrobiomik.
MBK-01 is designed to restore the balance of the gut microbiome in patients with recurrent Clostridioides difficile infections, a condition that severely affects patients’ quality of life and places a growing burden on healthcare systems.
‘We are demonstrating that microbiota-based therapies can be developed with the same scientific, industrial and regulatory rigour as any other drug,’ adds the CEO.
This breakthrough is the result of years of research, industrial development and, above all, clinical validation, and reinforces Mikrobiomik’s position as a pioneering biotechnology company in the field of the human microbiome in Europe. With our sights set on 2026, we continue to work to bring effective and safe therapy to thousands of patients.
‘We believe that the future of medicine lies in understanding and modulating the relationship between the host and its microbial ecosystem,’ concludes Del Río.
To read the full article, click the link below
